NeuBase Therapeutics (NeuBase Therapeutics) EBIT per Share : $-7.78 (TTM As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is NeuBase Therapeutics EBIT per Share?

NeuBase Therapeutics's EBIT per Share for the three months ended in Sep. 2023 was $-0.66. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-7.78.

During the past 3 years, the average EBIT per Share Growth Rate was 32.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was 46.10% per year. During the past 10 years, the average EBIT per Share Growth Rate was 11.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for NeuBase Therapeutics's EBIT per Share or its related term are showing as below:

NBSE' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -62.2 Med: -8.7 Max: 56.6
Current: 32.9

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of NeuBase Therapeutics was 56.60% per year. The lowest was -62.20% per year. And the median was -8.70% per year.

NBSE's 3-Year EBIT Growth Rate is ranked better than
82.84% of 1305 companies
in the Biotechnology industry
Industry Median: 3.2 vs NBSE: 32.90

NeuBase Therapeutics's EBIT for the three months ended in Sep. 2023 was $-1.82 Mil.

NeuBase Therapeutics EBIT per Share Historical Data

The historical data trend for NeuBase Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics EBIT per Share Chart

NeuBase Therapeutics Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

EBIT per Share

Get a 7-Day Free Trial

-212.96

-64.38

-62.81

-17.71

-18.59

NeuBase Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT per Share	Get a 7-Day Free Trial															-4.73	-2.65	-2.44	-2.04	-0.66

NeuBase Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

NeuBase Therapeutics's EBIT per Share for the fiscal year that ended in Sep. 2021 is calculated as

	EBIT per Share		(A: Sep. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-25.377	/	1.365
=	-18.59

NeuBase Therapeutics's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.821	/	2.758
=	-0.66

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.78

NeuBase Therapeutics (NAS:NBSE) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

NeuBase Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuBase Therapeutics (NeuBase Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

O7P:Germany O7P:Germany

Address

350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219

Website

https://www.neubasetherapeutics.com

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

Executives

Symetryx Corp	10 percent owner	2828 BATHURST ST #400, TORONTO A6 M6B3A7
Aleta Shiff	10 percent owner	461 LYTTON BLVD., TORONTO A6 M5N 1S5
Barry Shiff	10 percent owner	461 LYTTON BLVD., TORONTO A6 M5N 1S5
William Roland Mann	officer: COO	700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Todd P. Branning	officer: Chief Financial Officer	C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Sandra Rojas-caro	officer: Chief Medical Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746
Kianoush Motesharei	officer: See Remarks	350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Gerald J Mcdougall	director	350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Curt Bradshaw	officer: Chief Scientific Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Gines Diego Miralles	director	2235 VIA FRESCA, LA JOLLA CA 92037
Franklyn G Prendergast	director
Dietrich A Stephan	director, 10 percent owner, officer: President and CEO	213 SMITHFIELD ST, PITTSBURGH PA 15222
Lipizzaner Llc	10 percent owner	1209 ORANGE STREET, WILMINGTON DE 19801